MEP36208A - Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers - Google Patents

Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers

Info

Publication number
MEP36208A
MEP36208A MEP-362/08A MEP36208A MEP36208A ME P36208 A MEP36208 A ME P36208A ME P36208 A MEP36208 A ME P36208A ME P36208 A MEP36208 A ME P36208A
Authority
ME
Montenegro
Prior art keywords
combination
cytostatic
urea compounds
cytotoxic agents
human cancers
Prior art date
Application number
MEP-362/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Christopher A Carter
Jacques Dumas
Neil Gibson
Barbara Hibner
Rachel W Humphrey
Pamela Trail
Patrick W Vincent
Yifan Zhai
Bernd Riedl
Uday Khire
Timothy B Lowinger
William J Scott
Roger A Smith
Jill E Wood
Mary-Katherine Monahan
Reina Natero
Joel Renick
Robert N Sibley
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23307982&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP36208(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of MEP36208A publication Critical patent/MEP36208A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
MEP-362/08A 2001-12-03 2002-12-03 Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers MEP36208A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33460901P 2001-12-03 2001-12-03
PCT/US2002/038439 WO2003047579A1 (en) 2001-12-03 2002-12-03 Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers

Publications (1)

Publication Number Publication Date
MEP36208A true MEP36208A (en) 2011-02-10

Family

ID=23307982

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-362/08A MEP36208A (en) 2001-12-03 2002-12-03 Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers

Country Status (21)

Country Link
US (4) US20030232765A1 (ja)
EP (5) EP2305255B1 (ja)
JP (1) JP4982685B2 (ja)
AT (1) ATE345130T1 (ja)
AU (1) AU2002351196A1 (ja)
CA (1) CA2468463C (ja)
CY (2) CY1107440T1 (ja)
DE (2) DE60243587C5 (ja)
DK (2) DK1450799T5 (ja)
EC (2) ECSP045178A (ja)
ES (5) ES2275931T5 (ja)
HK (1) HK1155671A1 (ja)
ME (1) MEP36208A (ja)
MX (1) MXPA04005137A (ja)
NI (1) NI200400014A (ja)
PT (2) PT2305255E (ja)
RS (1) RS52500B (ja)
RU (1) RU2316326C2 (ja)
SI (2) SI1450799T1 (ja)
WO (1) WO2003047579A1 (ja)
ZA (1) ZA200404225B (ja)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2377847T3 (es) 1999-01-13 2012-04-02 Bayer Healthcare Llc Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US10653684B2 (en) 2002-02-11 2020-05-19 Bayer Healthcare Llc Aryl ureas with angiogenisis inhibiting activity
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
EP1474393A1 (en) 2002-02-11 2004-11-10 Bayer Pharmaceuticals Corporation Aryl ureas as kinase inhibitors
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
CA2526285A1 (en) 2003-05-15 2004-12-23 Arqule, Inc. Inhibitors of p38 and methods of using the same
DK1626714T3 (da) 2003-05-20 2007-10-15 Bayer Pharmaceuticals Corp Dirarylurinstoffer mod sygdomme medieret af PDGFR
RS52625B (en) 2003-07-23 2013-06-28 Bayer Healthcare Llc FLUORO SUBSTITUTED OMEGA-CARBOXYARYL DIPHENYL UREA FOR TREATMENT AND PREVENTION OF DISEASES AND DISEASES
TW200530236A (en) 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
US7459562B2 (en) * 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) * 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US7173031B2 (en) * 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7432373B2 (en) * 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
WO2006010082A1 (en) 2004-07-08 2006-01-26 Arqule, Inc. 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase
BRPI0515944B1 (pt) * 2004-09-29 2021-11-09 Bayer Healthcare Llc Processo para a preparação de 4-{4-[({[4-cloro-3-(trifluorometil)fe-nil]amino}carbonil) amino]fenóxi}nmetilpiridina-2-carboxamida
NZ553804A (en) * 2004-09-29 2010-07-30 Bayer Schering Pharma Ag Thermodynamically stable form of bay 43-9006 tosylate
JP2008517064A (ja) 2004-10-19 2008-05-22 アークル インコーポレイテッド Ｐ３８ｍａｐキナーゼのイミダゾオキサゾールおよびイミダゾチアゾール阻害剤の合成
MX2007010856A (es) * 2005-03-07 2007-11-12 Bayer Healthcare Ag Composicion farmaceutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cancer.
WO2007018137A1 (ja) 2005-08-05 2007-02-15 Chugai Seiyaku Kabushiki Kaisha マルチキナーゼ阻害剤
US20090068146A1 (en) 2005-10-31 2009-03-12 Scott Wilhelm Diaryl ureas and combinations
US20100144749A1 (en) * 2005-11-14 2010-06-10 Scott Wilhelm Treatment of cancers with acquired resistance to kit inhibitors
WO2007057440A2 (en) * 2005-11-17 2007-05-24 Innate Pharma Improved methods of using phosphoantigen for the treatment of cancer
GB0609378D0 (en) * 2006-05-11 2006-06-21 Novartis Ag Organic compounds
EP2094268A2 (en) 2006-05-26 2009-09-02 Bayer HealthCare, LLC Drug combinations with substituted diaryl ureas for the treatment of cancer
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
US20100029674A1 (en) * 2006-11-17 2010-02-04 Innate Pharma, S.A. Methods of Using Phosphoantigen for the Treatment of Cancer
JP5885012B2 (ja) 2007-01-19 2016-03-15 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅＬＬＣ Ｋｉｔ阻害剤に対して獲得した抵抗性を有する癌の処置
TW201012467A (en) * 2008-09-16 2010-04-01 Taiho Pharmaceutical Co Ltd Antitumor agent containing 4-[[3,5-bis(trimethylsilyl)benzoyl]amino]benzoic acid
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
AU2011264993B2 (en) * 2010-06-09 2014-02-06 Abbvie Bahamas Ltd. Solid dispersions containing kinase inhibitors
EP2595628A1 (en) 2010-07-19 2013-05-29 Bayer HealthCare LLC Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
MX2013003695A (es) 2010-10-01 2013-05-20 Bayer Ip Gmbh Combinaciones que contienen n-(2-arilamino) arilsulfonamida sustituida.
WO2012162025A1 (en) * 2011-05-20 2012-11-29 President And Fellows Of Harvard College Methods of selecting cancer patients for treatment with n,n'-diarylurea compounds and n,n'-diarylthiourea compounds
WO2013175506A2 (en) 2012-05-21 2013-11-28 Hetero Research Foundation Process for sorafenib tosylate polymorph iii
WO2015031604A1 (en) 2013-08-28 2015-03-05 Crown Bioscience, Inc. Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same
GB201507903D0 (en) * 2015-05-08 2015-06-24 Oncopeptides Ab Process for preparation of nitrogen mustard derivatives
CA3089630A1 (en) 2018-01-31 2019-08-08 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of mastocytosis
SG11202007198WA (en) 2018-01-31 2020-08-28 Deciphera Pharmaceuticals Llc Combination therapy for the treatment of gastrointestinal stromal tumors
TW202122082A (zh) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
EP4013412A1 (en) 2019-08-12 2022-06-22 Deciphera Pharmaceuticals, LLC Ripretinib for treating gastrointestinal stromal tumors
EP4084779B1 (en) 2019-12-30 2024-10-09 Deciphera Pharmaceuticals, LLC Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
EP4084778B1 (en) 2019-12-30 2023-11-01 Deciphera Pharmaceuticals, LLC Amorphous kinase inhibitor formulations and methods of use thereof
RU2766288C2 (ru) * 2020-03-30 2022-03-11 Общество с ограниченной ответственностью "АКСЕЛЬФАРМ" Аморфная форма 4-{ 4-[({ [4-хлор-3-(трифторметил)фенил]амино} карбонил)-амино]фенокси} -n-метилпиридин-2-карбоксамида тозилата (варианты), способ её получения и применение для лечения онкологических заболеваний
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US502504A (en) * 1893-08-01 Hermann thoms
US1792156A (en) * 1928-01-17 1931-02-10 Gen Aniline Works Inc 5-halogen-2-amino-1-alkyloxy and 1-aralkyloxy-benzenes and intermediate products thereof and process of preparing them
US2093265A (en) * 1931-03-31 1937-09-14 Ici Ltd Process for the manufacture of diaryl ureas
US2046375A (en) * 1931-06-04 1936-07-07 Ici Ltd p-halogen-omicron-alkoxy-aniline derivatives and process of preparing the same
US2288422A (en) * 1938-11-11 1942-06-30 Gen Aniline & Film Corp Mixed ureas
US2973386A (en) * 1943-01-05 1961-02-28 Harry A Weldon Purification of sym dichloro-bis (2, 4, 6-trichlorophenyl)urea
DE920245C (de) * 1950-04-29 1954-11-18 Variapat Ag Verfahren zur Herstellung von aromatischen, farblosen, wasserloeslichen Trifluormethyl- und Sulfosaeuregruppen enthaltenden unsymmetrischen Harnstoffen bzw. Thioharnstoffen
US2683082A (en) * 1950-12-09 1954-07-06 Ethyl Corp Nu-aryl-nu'-(p-hydroxyphenyl) ureas as antioxidants for petroleum hydrocarbon fuels
US2781330A (en) * 1953-02-09 1957-02-12 Monsanto Chemicals Rubber containing urea compound as an anti-exposure cracking agent
NL90162C (ja) * 1953-03-06
US2745874A (en) * 1953-06-18 1956-05-15 Geigy Ag J R Insecticidal derivatives of diphenyl urea
NL193403A (ja) * 1953-12-22 1924-02-17
US2877268A (en) * 1956-12-24 1959-03-10 Monsanto Chemicals Substituted ureas
NL254871A (ja) * 1959-08-14
BE616734A (ja) * 1961-04-21
US3200035A (en) * 1962-06-01 1965-08-10 Ciba Ltd Treatment of synthetic products, especially synthetic fibers
US3284433A (en) * 1963-07-17 1966-11-08 Merck & Co Inc 4-phenoxy-carbanilides
US3424762A (en) * 1966-03-07 1969-01-28 Robins Co Inc A H Certain 3-ureidopyrrolidines
US3424761A (en) * 1966-03-07 1969-01-28 Robins Co Inc A H 3-ureidopyrrolidines
US3424760A (en) * 1966-03-07 1969-01-28 Robins Co Inc A H 3-ureidopyrrolidines
US3743498A (en) * 1967-10-31 1973-07-03 Du Pont Method of selectively controlling undesirable vegetation
SE370866B (ja) * 1968-03-21 1974-11-04 Ciba Geigy Ag
US3754887A (en) * 1969-05-05 1973-08-28 Du Pont Ureidopyrazoles defoliants
US3646059A (en) * 1969-05-05 1972-02-29 Du Pont Plant growth regulatory ureidopyrazoles
BE754782A (fr) * 1969-08-14 1971-02-12 May & Baker Ltd Derives du thiophene a action herbicide
US3823161A (en) * 1970-05-07 1974-07-09 Exxon Research Engineering Co Aminothiophene derivatives
US3860645A (en) * 1973-05-23 1975-01-14 Givaudan Corp Bacteriostatic substituted carbanilides
US4212981A (en) * 1973-07-27 1980-07-15 Shionogi & Co., Ltd. Process for preparing 3-isoxazolylurea derivatives
US4111680A (en) * 1973-07-27 1978-09-05 Shionogi & Co., Ltd. Herbicidal compositions containing 3-isoxazolylurea derivatives
US4001256A (en) * 1973-12-26 1977-01-04 The Upjohn Company Pyridylalkyl phenyl ureas and their n-oxides
US4009847A (en) * 1974-04-17 1977-03-01 E. I. Du Pont De Nemours And Company 1-Tertiary-alkyl-3-(substituted thienyl)ureas and 1-tertiary-alkyl-3-(substituted thietyl)ureas as antihypertensive agents
US4111683A (en) * 1975-06-27 1978-09-05 Chevron Research Company N-alkyl or alkoxy-N'-substituted hydrocarbyl urea
US4071524A (en) * 1976-11-08 1978-01-31 Riker Laboratories, Inc. Derivatives of urea
US4183854A (en) * 1976-11-10 1980-01-15 John Wyeth & Brother Limited Thiazole compound
US4042372A (en) * 1976-11-19 1977-08-16 Eli Lilly And Company Substituted thiadiazolotriazinediones and method of preparation
JPS5562066A (en) * 1978-11-03 1980-05-10 Toshihiko Okamoto N-(2-substituted-4-pyridyl)-urea and thio urea, their preparation and plant growth regulator
JPS55124763A (en) * 1979-03-19 1980-09-26 Ishihara Sangyo Kaisha Ltd 5-trifluoromethyl-2-pyridone derivative
DE2928485A1 (de) * 1979-07-14 1981-01-29 Bayer Ag Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
US4468380A (en) * 1979-12-26 1984-08-28 Eli Lilly And Company Anticoccidial combinations comprising polyether antibiotics and carbanilides
US4526997A (en) * 1981-05-06 1985-07-02 Doherty George O P O Anticoccidial combinations comprising polyether antibiotics and carbanilides
US4511571A (en) * 1981-10-20 1985-04-16 Ciba Geigy Corporation N-(2-Pyridyloxyphenyl)-N'-benzoyl ureas, pesticidal compositions containing same and pesticidal methods of use
US4473579A (en) * 1982-01-26 1984-09-25 American Cyanamid Company Antiatherosclerotic tetrasubstituted ureas and thioureas
DE3211851A1 (de) * 1982-03-31 1983-10-06 Basf Ag Dihydrothiophen-carbonester, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
JPS58203957A (ja) * 1982-05-25 1983-11-28 Ube Ind Ltd 尿素誘導体の製法
CA1254212A (en) * 1982-11-12 1989-05-16 Shiro Hirai Amine derivatives, salts thereof, process for preparing the same and an anti-ulcer agent containing the same
DE3540377A1 (de) * 1985-11-14 1987-05-21 Bayer Ag Thienooxazinone, verfahren zu ihrer herstellung und ihre verwendung als leistungsfoerderer
DE3541631A1 (de) * 1985-11-26 1987-05-27 Bayer Ag Selektiv-fungizide verwendung von thienylharnstoff-derivaten
AU594098B2 (en) * 1985-12-11 1990-03-01 Ishihara Sangyo Kaisha Ltd. N-benzoyl urea compounds, antitumorous compositions containing them, and process for their preparation
EP0255297B1 (en) * 1986-07-31 1993-04-21 Beecham Group Plc Azabicyclic compounds, process for their preparation, and their pharmaceutical use
NZ221964A (en) * 1986-10-03 1990-03-27 Ishihara Sangyo Kaisha Benzoylurea compounds and insecticidal compositions
US4983605A (en) * 1986-10-23 1991-01-08 Ishihara Sangyo Kaisha Ltd. Pharmaceutical composition
DE3636190A1 (de) * 1986-10-24 1988-04-28 Bayer Ag Verfahren zur herstellung von n,n-diaryl-harnstoffen
JPH02237922A (ja) * 1989-01-24 1990-09-20 Green Cross Corp:The 抗ウィルス剤
JPH02196719A (ja) * 1989-01-24 1990-08-03 Green Cross Corp:The 粉末状医薬組成物
JP3002204B2 (ja) * 1989-03-13 2000-01-24 株式会社東芝 時系列信号認識装置
IL95860A0 (en) * 1989-10-13 1991-07-18 Ciba Geigy Ag Thienylthioureas,-isothioureas and-carbodiimides
CA2051705A1 (en) * 1990-06-19 1991-12-20 Kiyoaki Katano Pyridine derivatives having angiotensin ii antagonism
US5319099A (en) * 1991-01-21 1994-06-07 Shionogi Seiyaku Kabushiki Kaisha 3-benzylidene-1-carbamoyl-2-pyrrolidone compounds useful as antiinflammatory agents
US5185358A (en) * 1991-06-24 1993-02-09 Warner-Lambert Co. 3-heteroatom containing urea and thiourea ACAT inhibitors
US5508288A (en) * 1992-03-12 1996-04-16 Smithkline Beecham, P.L.C. Indole derivatives as 5HT1C antagonists
US5312820A (en) * 1992-07-17 1994-05-17 Merck & Co., Inc. Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines
DE4227989A1 (de) 1992-08-21 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
JP2717481B2 (ja) * 1992-08-25 1998-02-18 富士写真フイルム株式会社 ハロゲン化銀カラー写真感光材料
NZ264063A (en) * 1993-08-13 1995-11-27 Nihon Nohyaku Co Ltd N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions
US5596001A (en) * 1993-10-25 1997-01-21 Pfizer Inc. 4-aryl-3-(heteroarylureido)quinoline derivatves
CH686211A5 (de) * 1994-01-27 1996-02-15 Ciba Geigy Ag Motten- und Koferschutzmittel.
US5559137A (en) * 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
US5447957A (en) * 1994-06-02 1995-09-05 Smithkline Beecham Corp. Anti-inflammatory compounds
US5597719A (en) * 1994-07-14 1997-01-28 Onyx Pharmaceuticals, Inc. Interaction of RAF-1 and 14-3-3 proteins
EP0708085B1 (en) * 1994-10-19 2002-07-17 Novartis AG Antiviral ethers of aspartate protease substrate isosteres
CA2161376C (en) * 1994-10-27 2005-01-11 Toshiaki Minami Reversible multi-color thermal recording medium
US5780483A (en) * 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
WO1996025157A1 (en) * 1995-02-17 1996-08-22 Smithkline Beecham Corporation Il-8 receptor antagonists
US5814646A (en) * 1995-03-02 1998-09-29 Eli Lilly And Company Inhibitors of amyloid beta-protein production
DE19512639A1 (de) * 1995-04-05 1996-10-10 Merck Patent Gmbh Benzonitrile und -fluoride
US5773459A (en) * 1995-06-07 1998-06-30 Sugen, Inc. Urea- and thiourea-type compounds
CZ272296A3 (en) * 1995-09-18 1997-04-16 Sankyo Co Novel derivatives of urea exhibiting acat inhibition activity, their preparation and therapeutic and prophylactic application
AU1173997A (en) * 1995-12-28 1997-07-28 Kureha Kagaku Kogyo Kabushiki Kaisha Process for producing pyridinecarboxamides or thiocarboxamides
US6262113B1 (en) * 1996-03-20 2001-07-17 Smithkline Beecham Corporation IL-8 receptor antagonists
US6211373B1 (en) * 1996-03-20 2001-04-03 Smithkline Beecham Corporation Phenyl urea antagonists of the IL-8 receptor
US5891895A (en) * 1996-04-15 1999-04-06 Takeda Chemical Industries, Ltd. Hydroxypyridine derivatives their production and use
JPH09301858A (ja) * 1996-05-13 1997-11-25 Senju Pharmaceut Co Ltd グルコン酸クロルヘキシジン安定化水性薬剤
WO1997049400A1 (en) * 1996-06-27 1997-12-31 Smithkline Beecham Corporation Il-8 receptor antagonists
TR199802695T2 (xx) * 1996-06-27 1999-04-21 Smithkline Beecham Corporation IL-8 Resept�r kar��tlar�
FR2755967B1 (fr) * 1996-11-21 1999-01-29 Pf Medicament Derives de la pyridin-2-yl-methylamine, leur procede de preparation et leur application comme medicaments
US5929250A (en) * 1997-01-23 1999-07-27 Smithkline Beecham Corporation IL-8 receptor antagonists
JP2000510481A (ja) * 1997-04-04 2000-08-15 ファイザー・プロダクツ・インク ニコチンアミド誘導体
US6344476B1 (en) * 1997-05-23 2002-02-05 Bayer Corporation Inhibition of p38 kinase activity by aryl ureas
WO1998052559A1 (en) * 1997-05-23 1998-11-26 Bayer Corporation Raf kinase inhibitors
US6187799B1 (en) * 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
US6093742A (en) * 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
WO1999023091A1 (en) * 1997-11-03 1999-05-14 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6174901B1 (en) * 1998-12-18 2001-01-16 Amgen Inc. Substituted pyridine and pyridazine compounds and methods of use
ES2155045T3 (es) * 1997-12-22 2007-02-01 Bayer Pharmaceuticals Corp. Inhibicion de la quinasa raf utilizando ureas heterociclicas sustituidas con arilo y heteroarilo.
UA71904C2 (en) * 1997-12-22 2005-01-17 Compounds and methods of treating by inhibiting raf kinase using heterocyclic substituted urea derivatives
US6221913B1 (en) * 1998-01-21 2001-04-24 Zymogenetics, Inc. Dialkyl ureas as calcitonin mimetics
WO2000038715A2 (en) * 1998-12-23 2000-07-06 G.D. Searle & Co. Use of an integrin antagonist and radiation in the treatment of neoplasia
US20020065296A1 (en) * 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
US8124630B2 (en) * 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1140840B1 (en) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
TWI284642B (en) * 1999-01-18 2007-08-01 Hoffmann La Roche Novel heterocyclic sulfonamides
CZ301802B6 (cs) * 1999-03-19 2010-06-30 Vertex Pharmaceuticals Incorporated Deriváty mocoviny jako inhibitory IMPDH a farmaceutické prostredky s jejich obsahem
CA2370805C (en) * 1999-05-05 2012-07-03 Aventis Pharma Limited Ureas as cell adhesion modulators
DE19927835A1 (de) * 1999-06-18 2000-12-21 Clariant Gmbh Verwendung von verbesserten Cyanpigmenten in elektrophotographischen Tonern und Entwicklern, Pulverlacken und Ink-Jet-Tinten
US6387900B1 (en) † 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
US6420378B1 (en) † 1999-10-15 2002-07-16 Supergen, Inc. Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
GB9925958D0 (en) * 1999-11-02 1999-12-29 Bundred Nigel J Therapeutic use
GB0003201D0 (en) * 2000-02-11 2000-04-05 Pharmacia & Upjohn Spa Method to potentiate the therapeutic efficacy of taxane and derivatives thereof
MXPA02011218A (es) * 2000-05-15 2004-08-19 Celgene Corp Composiciones y metodos para el tratamiento de cancer.
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
US20020173507A1 (en) † 2000-08-15 2002-11-21 Vincent Santora Urea compounds and methods of uses
US7238813B2 (en) † 2000-11-29 2007-07-03 Smithkline Beecham Corporation Chemical compounds
SI1478358T1 (sl) * 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
DK1626714T3 (da) * 2003-05-20 2007-10-15 Bayer Pharmaceuticals Corp Dirarylurinstoffer mod sygdomme medieret af PDGFR

Also Published As

Publication number Publication date
RS48804A (en) 2006-12-15
AU2002351196A1 (en) 2003-06-17
ES2275931T3 (es) 2007-06-16
EP2295057A1 (en) 2011-03-16
EP2305256B1 (en) 2012-10-24
EP1450799A1 (en) 2004-09-01
DE60216139T2 (de) 2007-09-06
DE60216139D1 (de) 2006-12-28
ES2426938T8 (es) 2018-08-23
DK1450799T5 (da) 2007-09-17
ATE345130T1 (de) 2006-12-15
PT2305255E (pt) 2012-09-04
MXPA04005137A (es) 2005-06-03
EP1769795A3 (en) 2008-03-12
PT1450799E (pt) 2007-01-31
ES2275931T5 (es) 2018-10-23
EP2305256A1 (en) 2011-04-06
CY1113160T1 (el) 2016-04-13
ES2426938T3 (es) 2013-10-25
US20120040925A1 (en) 2012-02-16
EP2305255B1 (en) 2012-08-22
SI1450799T1 (sl) 2007-02-28
RU2004120785A (ru) 2005-04-10
CY1107440T1 (el) 2012-12-19
JP4982685B2 (ja) 2012-07-25
DE60243587C5 (de) 2024-04-18
SI2305255T1 (sl) 2012-10-30
CA2468463A1 (en) 2003-06-12
CA2468463C (en) 2013-06-18
ES2391382T3 (es) 2012-11-23
ECSP105178A (es) 2010-03-31
WO2003047579A1 (en) 2003-06-12
US20030232765A1 (en) 2003-12-18
RU2316326C2 (ru) 2008-02-10
ECSP045178A (es) 2005-03-10
JP2005511658A (ja) 2005-04-28
DK1450799T3 (da) 2007-03-19
NI200400014A (es) 2006-08-23
US20060247186A1 (en) 2006-11-02
EP1769795A2 (en) 2007-04-04
ES2400070T3 (es) 2013-04-05
ES2393900T3 (es) 2012-12-28
ES2391382T8 (es) 2018-08-23
EP1450799B1 (en) 2006-11-15
HK1155671A1 (en) 2012-05-25
RS52500B (en) 2013-04-30
EP1450799B2 (en) 2018-07-11
EP1450799B9 (en) 2007-05-09
EP1769795B1 (en) 2013-07-24
DE60216139T3 (de) 2018-11-15
EP2305255A1 (en) 2011-04-06
DK2305255T3 (da) 2012-12-10
WO2003047579B1 (en) 2003-08-21
ZA200404225B (en) 2005-08-29
EP2295057B1 (en) 2013-01-23
US20140336210A1 (en) 2014-11-13

Similar Documents

Publication Publication Date Title
MEP36208A (en) Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
HK1096392A1 (en) Substituted heterocycles
DE602005025803D1 (de) Stereoisomerisch angereicherte 3-aminocarbonyl-bicyclohepten-pyrimidindiamin-verbindungen und ihre verwendungen
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
UA92503C2 (ru) Соединения 5-(фенилизоксазолилэтокси)-триазол-3-ил-замещенного пиридина для лечения неврологических, психиатрических или болевых расстройств
ME00275B (me) ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
MEP36908A (en) omega-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
ATE408601T1 (de) Fredericamycin-derivate
BG66080B1 (bg) Заместени тиоацетамиди
MXPA05009885A (es) Nuevas triazolonas fusionadas y los usos de las mismas.
MY133995A (en) 6-phenylpyrrolopyrimidinedione derivatives
EP1427418A4 (en) PIPERAZINONE COMPOUNDS AS ANTITUMOR AND ANTICANCER AGENTS AND METHODS OF TREATMENT
SE0302304D0 (sv) Novel compounds
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
FR2877667B1 (fr) Derives de 4,7-dioxobenzothiazole-2-carboxamides, leur preparation et leurs applications therapeutiques
DE60334289D1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen
PE20030125A1 (es) PIRIDO[1,2-c]PIRIMIDINA COMO AGENTES ANTIBACTERIANOS
ATE411313T1 (de) Neue makrocyclen zur behandlung von krebserkrankungen
ECSP003318A (es) UREAS DIFENIL -w -CARBOXIARIL SUBSTITUIDAS COMO INHIBIDORES DE RAF QUINASA
TW200505440A (en) Novel fused triazolones and the uses thereof